Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
St. Francis Cancer Care Services
mi
from
Beech Grove, IN
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
St. Francis Cancer Care Services
mi
from
Beech Grove, IN
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
Indiana Cancer Pavillion
mi
from
Indianapolis, IN
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Indiana Cancer Pavillion
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
LSU Shreveport
mi
from
Shreveport, LA
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
LSU Shreveport
mi
from
Shreveport, LA
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
Univeristy of Maryland Medicine - Greenebaum Cancer Center
mi
from
Baltimore, MD
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Univeristy of Maryland Medicine - Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
Johns Hopkins
mi
from
Baltimore, MD
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
Tufts - New England Medical Center
mi
from
Boston, MA
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Tufts - New England Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
Beth Israel Hospital
mi
from
Boston, MA
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Beth Israel Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
University of Michigan
mi
from
Ann Arbor, MI
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
Karmanos Cancer Institute/Wayne State University
mi
from
Detroit, MI
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Karmanos Cancer Institute/Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
Univ of Minnesota
mi
from
Minneapolis, MN
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
The Mayo Clinic
mi
from
Rochester, MN
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
Washington University
mi
from
St. Louis, MO
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
University of Nebraska
mi
from
Omaha, NE
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
University of Nebraska
mi
from
Omaha, NE
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
New York Presbyterian
mi
from
New York, NY
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
New York Presbyterian
mi
from
New York, NY
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
Medical University of South Carolina
mi
from
Charleston, SC
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
ACORN - The West Clinic
mi
from
Memphis, TN
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
ACORN - The West Clinic
mi
from
Memphis, TN
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
University of Washington Medical Center
mi
from
Seattle, WA
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated:  3/16/2016
mi
from
Sydney,
Study of CEP-701 (Lestaurtinib) in Patients With Acute Myeloid Leukemia (AML)
A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence With Standard Chemotherapy to Patients With Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations
Status: Enrolling
Updated: 3/16/2016
mi
from
Sydney,
Click here to add this to my saved trials
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Hot Springs, AR
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Hot Springs, AR
Click here to add this to my saved trials
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Rancho Cucamonga, CA
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Rancho Cucamonga, CA
Click here to add this to my saved trials
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Norwich, CT
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Norwich, CT
Click here to add this to my saved trials
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Jacksonville, FL
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
New Port Richey, FL
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
New Port Richey, FL
Click here to add this to my saved trials
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Rome, GA
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Rome, GA
Click here to add this to my saved trials
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Savannah, GA
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Savannah, GA
Click here to add this to my saved trials
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Wichita, KA
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Wichita, KA
Click here to add this to my saved trials
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Bethesda, MD
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Bethesda, MD
Click here to add this to my saved trials
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Rockville, MD
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Rockville, MD
Click here to add this to my saved trials
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Columbia, MO
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Columbia, MO
Click here to add this to my saved trials
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Las Vegas, NV
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Cherry Hill, NJ
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Cherry Hill, NJ
Click here to add this to my saved trials
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Albany, NY
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Albany, NY
Click here to add this to my saved trials
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Greensboro, NC
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Greensboro, NC
Click here to add this to my saved trials
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Bend, OR
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Bend, OR
Click here to add this to my saved trials
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Philadelphia, PA
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Wynnewood, PA
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Wynnewood, PA
Click here to add this to my saved trials
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Providence, RI
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Providence, RI
Click here to add this to my saved trials
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Providence, RI
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Providence, RI
Click here to add this to my saved trials
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Greenville, SC
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Greenville, SC
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Greenville, SC
Click here to add this to my saved trials
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Arlington, TX
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Arlington, TX
Click here to add this to my saved trials
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Austin, TX
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated:  3/17/2016
GSK Investigational Site
mi
from
Bedford, TX
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag
A Randomized, Blinded, Placebo-controlled, Two-Phase, Sequential Cohort, Dose Finding Study to Assess the Safety and Efficacy of an Oral Thrombopoietin Receptor Agonist, Eltrombopag (SB-497115-GR), Administered to Patients With Solid Tumors Receiving Gemcitabine Monotherapy or the Combination of Gemcitabine Plus Carboplatin or Cisplatin
Status: Enrolling
Updated: 3/17/2016
GSK Investigational Site
mi
from
Bedford, TX
Click here to add this to my saved trials